Latest Search
Quote
| Back Zoom + Zoom - | ||||
|
Ascletis Pharma-B (01672.HK) Completes Enrollment in US Phase II Study of Oral Small Molecule GLP-1R Agonist ASC30
Recommend 4 Positive 8 Negative 1 |
||||
|
||||
|
Ascletis Pharma-B (01672.HK) announced that enrollment has been completed in its 13-week US Phase II study (NCT07321678) evaluating the oral small molecule GLP-1 receptor (GLP-1R) agonist ASC30 for the treatment of type 2 diabetes. Type 2 diabetes is the second indication for ASC30 following obesity, its first indication. Topline data from this Phase II study for the treatment of type 2 diabetes are expected to be available in 3Q26. (ec/w) This article was automatically translated by AI, the Chinese version should be considered the authoritative version. AASTOCKS.com Limited does not guarantee its accuracy or completeness and accepts no liability for any damages or losses arising from the use of this translation. Auto-translated by AI AASTOCKS Financial News |
||||
Copied to Clipboard
 |
||||
